38.78 USD
-1.44 (-3.57%)
38.78 USD
0 (0%)
Taking everything into account, IMCR scores 4 out of 10 in our fundamental rating. IMCR was compared to 531 industry peers in the Biotechnology industry. While IMCR seems to be doing ok healthwise, there are quite some concerns on its profitability. IMCR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
IMCR had negative earnings in the past year.
In the past year IMCR had a positive cash flow from operations.
In the past 5 years IMCR always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: IMCR reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of IMCR (-2.65%) is better than 87.29% of its industry peers.
IMCR's Return On Equity of -7.37% is amongst the best of the industry. IMCR outperforms 88.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.65% | ||
| ROE | -7.37% | ||
| ROIC | N/A |
ROA(3y)-7.93%
ROA(5y)-20.99%
ROE(3y)-14.64%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMCR's Gross Margin of 99.28% is amongst the best of the industry. IMCR outperforms 98.13% of its industry peers.
IMCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMCR has about the same amount of shares outstanding.
Compared to 5 years ago, IMCR has more shares outstanding
The debt/assets ratio for IMCR is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.79, we must say that IMCR is in the distress zone and has some risk of bankruptcy.
IMCR's Altman-Z score of 1.79 is fine compared to the rest of the industry. IMCR outperforms 65.98% of its industry peers.
IMCR has a debt to FCF ratio of 133.17. This is a negative value and a sign of low solvency as IMCR would need 133.17 years to pay back of all of its debts.
IMCR has a Debt to FCF ratio of 133.17. This is amongst the best in the industry. IMCR outperforms 89.35% of its industry peers.
IMCR has a Debt/Equity ratio of 0.99. This is a neutral value indicating IMCR is somewhat dependend on debt financing.
The Debt to Equity ratio of IMCR (0.99) is worse than 77.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.99 | ||
| Debt/FCF | 133.17 | ||
| Altman-Z | 1.79 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
A Current Ratio of 6.00 indicates that IMCR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.00, IMCR is in the better half of the industry, outperforming 62.24% of the companies in the same industry.
A Quick Ratio of 5.97 indicates that IMCR has no problem at all paying its short term obligations.
The Quick ratio of IMCR (5.97) is better than 63.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6 | ||
| Quick Ratio | 5.97 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 40.00% over the past year.
IMCR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -20.18%.
Measured over the past years, IMCR shows a very strong growth in Revenue. The Revenue has been growing by 64.57% on average per year.
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-20.18%
Revenue growth 3Y127.06%
Revenue growth 5Y64.57%
Sales Q2Q%29.22%
3.2 Future
IMCR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.23% yearly.
The Revenue is expected to grow by 21.89% on average over the next years. This is a very strong growth
EPS Next Y59.52%
EPS Next 2Y-9.29%
EPS Next 3Y-10.31%
EPS Next 5Y36.23%
Revenue Next Year27.67%
Revenue Next 2Y18.78%
Revenue Next 3Y17.05%
Revenue Next 5Y21.89%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IMCR. In the last year negative earnings were reported.
Also next year IMCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, IMCR is valued cheaply inside the industry as 89.35% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 664.71 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IMCR's earnings are expected to decrease with -10.31% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.29%
EPS Next 3Y-10.31%
5. Dividend
5.1 Amount
No dividends for IMCR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
38.78
-1.44 (-3.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.15%
Inst Owner Change7.93%
Ins Owners0.03%
Ins Owner Change0%
Market Cap1.96B
Revenue(TTM)379.59M
Net Income(TTM)-29.23M
Analysts81.74
Price Target69.09 (78.16%)
Short Float %17.75%
Short Ratio27.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.15%
Min EPS beat(2)0.3%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)36.51%
Min EPS beat(4)-79.43%
Max EPS beat(4)125.17%
EPS beat(8)5
Avg EPS beat(8)33.88%
EPS beat(12)7
Avg EPS beat(12)-206116%
EPS beat(16)10
Avg EPS beat(16)-154570%
Revenue beat(2)2
Avg Revenue beat(2)1.41%
Min Revenue beat(2)1.34%
Max Revenue beat(2)1.47%
Revenue beat(4)3
Avg Revenue beat(4)0.81%
Min Revenue beat(4)-4.08%
Max Revenue beat(4)4.49%
Revenue beat(8)4
Avg Revenue beat(8)-0.21%
Revenue beat(12)7
Avg Revenue beat(12)1.11%
Revenue beat(16)11
Avg Revenue beat(16)24.91%
PT rev (1m)2.82%
PT rev (3m)7.63%
EPS NQ rev (1m)6.43%
EPS NQ rev (3m)26.47%
EPS NY rev (1m)43.75%
EPS NY rev (3m)49.06%
Revenue NQ rev (1m)1.7%
Revenue NQ rev (3m)0.06%
Revenue NY rev (1m)1.7%
Revenue NY rev (3m)0.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.16 | ||
| P/FCF | 664.71 | ||
| P/OCF | 245.19 | ||
| P/B | 4.94 | ||
| P/tB | 4.94 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.57
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)0.06
FCFY0.15%
OCF(TTM)0.16
OCFY0.41%
SpS7.51
BVpS7.85
TBVpS7.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.65% | ||
| ROE | -7.37% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.29% | ||
| FCFM | 0.78% |
ROA(3y)-7.93%
ROA(5y)-20.99%
ROE(3y)-14.64%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.99 | ||
| Debt/FCF | 133.17 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 140.19% | ||
| Cap/Sales | 1.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6 | ||
| Quick Ratio | 5.97 | ||
| Altman-Z | 1.79 |
F-Score6
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)97.19%
Cap/Depr(5y)68.03%
Cap/Sales(3y)1.79%
Cap/Sales(5y)3.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y59.52%
EPS Next 2Y-9.29%
EPS Next 3Y-10.31%
EPS Next 5Y36.23%
Revenue 1Y (TTM)-20.18%
Revenue growth 3Y127.06%
Revenue growth 5Y64.57%
Sales Q2Q%29.22%
Revenue Next Year27.67%
Revenue Next 2Y18.78%
Revenue Next 3Y17.05%
Revenue Next 5Y21.89%
EBIT growth 1Y59.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.31%
EBIT Next 3Y-9.53%
EBIT Next 5Y36.15%
FCF growth 1Y-77.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.3%
OCF growth 3YN/A
OCF growth 5YN/A
IMMUNOCORE HOLDINGS PLC-ADR / IMCR FAQ
What is the ChartMill fundamental rating of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?
ChartMill assigns a fundamental rating of 4 / 10 to IMCR.
Can you provide the valuation status for IMMUNOCORE HOLDINGS PLC-ADR?
ChartMill assigns a valuation rating of 2 / 10 to IMMUNOCORE HOLDINGS PLC-ADR (IMCR). This can be considered as Overvalued.
How profitable is IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) has a profitability rating of 3 / 10.
What is the earnings growth outlook for IMMUNOCORE HOLDINGS PLC-ADR?
The Earnings per Share (EPS) of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) is expected to grow by 59.52% in the next year.